TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8296092
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine (5 x 10^9 FU)
Study: 30150192
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder (GP) at a dose rate of 2 g/day
Study: 30150192
Drug: Coriander seed
Normalized name: coriander seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coriander seed powder (CSP) at a dose rate of 2 g/day
Study: 30150192
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of garlic powder and coriander seed powder (1:1 dry weight basis) at a dose rate of 2 g/day
Study: 17725303
Drug: Vardenafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (10 mg to 20 mg for 2 months)
Study: 17725303
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily for 2 months)
Study: 15470715
Drug: Sequential irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential irinotecan plus bolus 5‐FU/LV (Arm B)
Study: 8914949
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil capsules containing 1.5-1.8 g of DHA
Study: 8914949
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil capsules containing 97% soybean oil and 3% fish oil
Study: 31477161
Drug: Febuxostat 20
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 20 mg daily
Study: 31477161
Drug: Benzbromarone 25
Normalized name: benzbromarone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone 25 mg daily
Study: 16982294
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg QD for 5 days
Study: 16982294
Drug: Amoxicillin/clavulanate 875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 875 mg/125 mg BID for 10 days
Study: 9333066
Drug: Cefodizime (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (single 2‐g intravenous dose)
Study: 9333066
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single 2‐g intravenous dose)
Study: 8265839
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg q.d.s.)
Study: 8265839
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (10 mg q.d.s.)
Study: 26321218
Drug: Inhaled Alpha‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Alpha‐1 HC 100 mg
Study: 26321218
Drug: Inhaled Alpha‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Alpha‐1 HC 200 mg
Study: 23890273
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Pegylated interferon (160 μg weekly) + Ribavirin (1200 mg if ≥ 75 kg, 1000 mg if <75 kg) for 48 weeks
Study: 23890273
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Nitazoxanide (500 mg bid for 4 weeks lead-in) + Pegylated interferon + Ribavirin for 48 weeks
Study: 16599102
Drug: Intensive nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive nutrition education (INE) twice a week for three months
Study: 16599102
Drug: Intensive nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive nutrition education with supplementary feeding (INE+SF) twice a week for three months
Study: 16599102
Drug: Standard routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard routine nutrition education from community nutrition promoters twice a month
Study: 9732938
Drug: Dual therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy: Lansoprazole (30 mg b.i.d.) and Amoxicillin (1 g b.i.d.)
Study: 9732938
Drug: Triple therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy: Lansoprazole (30 mg b.i.d.), Amoxicillin (1 g b.i.d.), and Clarithromycin (500 mg b.i.d.)
Study: 2525998
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + Hydrochlorothiazide 25 mg (group A)
Study: 2525998
Drug: Amiloride 5
Normalized name: amiloride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 5 mg + Hydrochlorothiazide 50 mg (group B)
Study: 8803642
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (enoxaparin 40 mg once daily)
Study: 8803642
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once daily) plus graduated elastic compression (TEDR stockings) for 8-12 days
Study: 1387231
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g fish oil preparation
Study: 1387231
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g fish oil preparation
Study: 1387231
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g fish oil preparation
Study: 1387231
Drug: Both fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both fish oil preparations
Study: 6436897
Drug: Haloperidol 16
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 16 mg per day (low dose)
Study: 6436897
Drug: Haloperidol 80
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 80 mg per day (high dose)
Study: 29423774
Drug: Glucose levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose levels above the median (11.5 mmol/L)
Study: 26616224
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 administered over a 3 hour infusion, cycling every 21 days
Study: 18619799
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber therapy
Study: 8910627
Drug: Any antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antigen preparation
Study: 8910627
Drug: High antibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antibody titers
Study: 6873561
Drug: Propantheline bromide
Normalized name: Propantheline Bromide
DrugBank: Propantheline (DB00782)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propantheline bromide (anticholinergic agent)
Study: 2579597
Drug: Intraderma injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderma injection of terbutaline (0.25-100 ng)
Study: 2579597
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline and theophylline treatment
Study: 22849416
Drug: Blind lineup
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind lineup administration (presumed blind condition)
Study: 22849416
Drug: Non-blind lineup
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-blind lineup administration (presumed nonblind condition)
Study: 14520027
Drug: Fat-modified diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-modified diet with caloric restriction and daily intake of 35-50 g oat bran
Study: 10655911
Drug: Propofol 3-4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 3-4 mg kg-1 with succinylcholine 2 mg kg-1
Study: 8887260
Drug: Prednisolone in
Normalized name: methylprednisolone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone in combination with other immunosuppressants
Study: 8887260
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment protocols
Study: 1649265
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with cyclophosphamide, doxorubicin, and vincristine (CAV)
Study: 26391623
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs), n = 5
Study: 26391623
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drugs (AADs), n = 8
Study: 21663809
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (50 mg)
Study: 19636011
Drug: rhITF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhITF 10 mg/mL (low dose)
Study: 19636011
Drug: rhITF 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhITF 80 mg/mL (high dose)
Study: 15288082
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 30% saccharose solution with non nutritive pacifier sucking (S)
Study: 15288082
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 30% saccharose solution with local application of Emla and with non nutritive pacifier sucking (S + E)
Study: 8164926
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined regimen with 2.5 mg of MPA (Group A)
Study: 8164926
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined regimen with 5.0 mg of MPA (Group B)
Study: 8164926
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen with 5.0 mg of MPA (Group C)
Study: 8164926
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen with 10.0 mg of MPA (Group D)
Study: 26293750
Drug: Fewer drug-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fewer drug-related problems
Study: 26293750
Drug: No use
Approvals — FDA: no, EMA: no, PMDA: no
Description: No use of hard drugs within the prior 30 days
Study: 25601341
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily)
Study: 20233897
Drug: 7.5% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% CO2 inhalation for 20 minutes
Study: 20233897
Drug: 7.5% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% CO2 inhalation on day 2
Study: 16820555
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (1 to 3 mg/h for 48 hours)
Study: 16820555
Drug: Oral metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoprolol (25 mg twice per day to 50 mg 3 times per day starting on the first postoperative morning)
Study: 10849056
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Study: 10849056
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Study: 27365164
Drug: Capillary drug
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capillary drug concentrations after administration of a single dose of antipsychotic drugs
Study: 27365164
Drug: Venous drug
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous drug concentrations after administration of a single dose of antipsychotic drugs
Study: 22963750
Drug: G-CSF/CPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF/CPC
Study: 18476965
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 100 mg (group III)
Study: 18476965
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 25 mg (group II)
Study: 18476965
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral sildenafil 100 mg (group V)
Study: 18476965
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral placebo (group IV)
Study: 18476965
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral placebo (group I)
Study: 29161349
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and zeaxanthin (L&Z)
Study: 17313848
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (tacrolimus + glucocorticoid)
Study: 17313848
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid)
Study: 17313848
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid + daclizumab)
Study: 12638645
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for tobacco dependence in alcoholic smokers
Study: 12638645
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy and 12-step approaches
Study: 12638645
Drug: Further research
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Further research on effective treatments
Study: 10798820
Drug: Lamotrigine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (25 mg once daily for 1 week, 50 mg once daily for the second week, and 100 mg once daily for the last 2 weeks)
Study: 10798820
Drug: Lithium (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (400 mg twice daily)
Study: 7625346
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement (SL; 300 micrograms/d, n = 14)
Study: 2522902
Drug: Long-acting GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting GnRH agonist (3.2 mg intramuscularly)
Study: 2522902
Drug: Combined GnRH-agonist/gonadotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined GnRH-agonist/gonadotropin stimulation
Study: 331057
Drug: Kavain (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kavain (200 mg per capsule, 2 capsules per day)
Study: 20197485
Drug: CS-8958 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-8958 (20 mg inhaled dose)
Study: 19811351
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LOS + 25 mg HCTZ (test formulation)
Study: 19811351
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Hyzaar)
Study: 16762012
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (TA) injection (0.5 ml at 40 mg/ml)
Study: 14770445
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa fixed dose (325 microg)
Study: 14770445
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa weight-based dose (4.5 microg/kg)
Study: 11423594
Drug: Active TENS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TENS plus standard medication
Study: 11423594
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication only (midazolam)
Study: 11423594
Drug: Non‐functioning TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐functioning TENS and standard medication
Study: 25494967
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 2000 or 500 mg
Study: 25494967
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (ivMP) 7.5 g
Study: 22018131
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel)
Study: 22018131
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal rings (daily release of 15 mcg ethinyl estradiol/120 mcg etonogestrel)
Study: 10787361
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 1380)
Study: 1485178
Drug: Ondansetron 1
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 1 mg, 4 mg, or 8 mg, three times per day for 3 days
Study: 1485178
Drug: Ondansetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (all doses)
Study: 6729868
Drug: Pendulum therapy
Normalized name: Aconitum pendulum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pendulum therapy (2000 cGy in ten fractions)
Study: 6729868
Drug: Stationary field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stationary field therapy (2000 cGy in ten fractions)
Study: 30367673
Drug: Sucrose vaginal
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose vaginal gel
Study: 24346164
Drug: Multilevel models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilevel models with varying individual-level variances and correlations across treatment arms
Study: 24346164
Drug: Multilevel models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilevel models with fixed individual-level variances and correlations across treatment arms
Study: 18435426
Drug: Lung-volume-reduction surgery
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-volume-reduction surgery plus medical therapy
Study: 11419683
Drug: Mebendazole 200
Normalized name: mebendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 200 mg thrice daily for 5 days
Study: 11419683
Drug: Metronidazole 15
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 15 mg/kg/day in three divided doses for 7 days
Study: 9268175
Drug: Dalteparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (low molecular weight heparin), given subcutaneously once daily
Study: 9268175
Drug: Unfractionated heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin, continuous intravenous infusion
Study: 8111817
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core 30 mg/day
Study: 8111817
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core 60 mg/day
Study: 8111817
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core 90 mg/day
Study: 8111817
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core (all doses)
Study: 3103730
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg aminohydroxypropylidene diphosphonate
Study: 934677
Drug: New variants
Approvals — FDA: no, EMA: no, PMDA: no
Description: New variants of the Pinkel treatment scheme
Study: 27259298
Drug: Hypoglycemic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic and antihypertensive drug use
Study: 20679904
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ilaprazole
Study: 20679904
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ilaprazole
Study: 20679904
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ilaprazole
Study: 16834791
Drug: Meptazinol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (2.5 mg kg‐1)
Study: 15704320
Drug: LifeSite Hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LifeSite Hemodialysis System with 70% isopropyl alcohol as the antimicrobial solution
Study: 11697835
Drug: Oral capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine 1,255 mg/m2 twice daily (two weeks' treatment followed by a one-week rest period)
Study: 11697835
Drug: Intravenous CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil) administered every three weeks
Study: 9208260
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 treatment
Study: 9208260
Drug: Normal controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal controls (before treatment)
Study: 30305092
Drug: Otic gel
Normalized name: Otic Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otic gel containing 1% florfenicol, 1% terbinafine and 0.1% betamethasone acetate applied twice with a one‐week interval
Study: 30305092
Drug: Suspension containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension containing hydrocortisone aceponate, miconazole and gentamicin administered daily for 5 days